Developer docs
API playgroundTry for free, no card

Search company profiles

Damora Therapeutics

Full company profile

uuid003vofi

Namestring
Damora Therapeutics
Legal namestring
Damora Therapeutics, Inc.
Websiteurl
damoratx.com
Company typeenum
Public
Founded yearint
2025
Descriptiontext

Damora Therapeutics (NASDAQ: DMRA) is a pre-revenue, clinical-stage biotechnology company headquartered in the Boston area and domiciled in Massachusetts, developing a new generation of disease-modifying monoclonal antibody biologics targeting mutant calreticulin (mutCALR), the disease driver in approximately 25% of essential thrombocythemia and 35% of myelofibrosis cases, a U.S. patient population of roughly 42,000. The lead asset, DMR-001, is engineered for exclusive mutCALR binding, with preclinical data showing approximately 10-fold potency gain against Type 2 mutant cells and approximately 5-fold half-life extension versus a relevant reference antibody, enabling subcutaneous autoinjector administration. The pipeline contains four programs (DMR-001 through DMR-004) using diverse modalities across the Type 1 and Type 2 CALR mutation spectrum, with regulatory submission for DMR-001 planned for mid-2026 and proof-of-concept clinical datasets expected beginning mid-2027.

The company was formed via Galecto, Inc.'s November 2025 acquisition of the original Damora Therapeutics and a concurrent oversubscribed private placement of approximately $284.9 million, followed by rebranding from Galecto to Damora and a $316 million public offering in March 2026. The cash position was approximately $532.9 million as of March 31, 2026, funding operations into 2029. Leadership is anchored by CEO Jennifer Jarrett (former COO/CFO of Arcus Biosciences, CFO of Medivation) alongside several former Blueprint Medicines executives (COO Sherwin Sattarzadeh, CMO Dr. Becker Hewes, CCO Jim Baker) and a board chaired by Peter Harwin of Fairmount Funds Management.

The business model is contingent on regulatory approval. Planned go-to-market channels include pharmaceutical distribution through specialty pharmacies, hospital buying groups, and academic medical centers, leveraging the subcutaneous autoinjector format for patient self-administration. Pricing has not been publicly disclosed. Sell-side analysts at TD Cowen, RBC Capital, Evercore ISI, and Leerink project peak sales of approximately $3.3 billion for DMR-001 in myelofibrosis and $3 billion in essential thrombocythemia. FY2025 net loss was approximately $209.84 million and Q1 2026 net loss was $27.8 million, reflecting elevated R&D investment ahead of clinical trials.

Short descriptiontext

Damora Therapeutics is a pre-revenue, clinical-stage biotechnology company developing monoclonal antibody biologics targeting mutant calreticulin for the treatment of mutant CALR-driven myeloproliferative neoplasms (essential thrombocythemia and myelofibrosis), serving an addressable U.S. population of approximately 42,000 patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
monoclonal antibody therapy, myeloproliferative neoplasm treatment, rare disease biologics, oncology drug development, calreticulin targeted therapeutics
Industry1 code
PRIMARYHLAAAAAL
Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Biopharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Damora Therapeutics is a pre-revenue biotechnology company that has not yet commercialized any products. The company is developing DMR-001 and additional pipeline assets for mutant CALR-driven myeloproliferative neoplasms. Upon regulatory approval, the company plans to generate revenue through the sale of pharmaceutical products, initially focusing on the U.S. market with plans for global expansion through clinical development.

stocktitan.net
2Potential Licensing and Partnership Revenue
TypeLicensing Royalties
Description

As a development-stage biotech company, Damora may pursue licensing agreements, co-development partnerships, or strategic collaborations to advance its pipeline and generate revenue. TD Cowen coverage cited $3.3 billion peak sales forecast for DMR-001 in myelofibrosis and $3 billion in essential thrombocythemia, indicating significant commercial potential.

in.investing.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Damora Therapeutics develops a pipeline of investigational monoclonal antibody therapeutics designed to exclusively target mutant calreticulin (mutCALR) for the treatment of myeloproliferative neoplasms, specifically Essential Thrombocythemia and Myelofibrosis. The lead asset, DMR-001, is engineered with clinically validated half-life extension technology to enable convenient, infrequent subcutaneous administration via autoinjector, offering a first-in-class disease-modifying approach for approximately 42,000 U.S. patients with no currently approved targeted therapy available.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 10-fold increase in potency against Type 2 mutant cells compared to reference antibody
+3 more records
Product overview1 text field

Damora Therapeutics is developing a pipeline of targeted biologics (monoclonal antibodies) for mutant calreticulin-driven myeloproliferative neoplasms (MPNs). The company's lead asset is DMR-001, an investigational monoclonal antibody therapy targeting mutCALR with best-in-class potential. The pipeline includes multiple programs (DMR-001, DMR-002, DMR-003, DMR-004) all targeting the same disease driver but leveraging diverse modalities to address the full spectrum of MPN patients. DMR-001 is the most advanced, with plans for regulatory submission in mid-2026 and Phase 1/1b clinical trial initiation, with proof-of-concept data expected beginning mid-2027.

Product and service4 records
1DMR-001
CategoryOncology Biologics / Targeted Therapy
Description

DMR-001 is an investigational monoclonal antibody therapy targeting mutant calreticulin (mutCALR) with best-in-class potential for treating Essential Thrombocythemia (ET) and Myelofibrosis (MF). It is engineered for high selectivity and potency, with extended half-life to enable convenient, infrequent subcutaneous administration via autoinjector. Preclinical data show approximately 10-fold higher potency against Type 2 mutant cells and approximately 5-fold longer half-life compared to a reference antibody. Damora plans regulatory submission in mid-2026 to enable a global Phase 1/1b trial, with proof-of-concept data expected beginning in mid-2027.

2DMR-002
CategoryOncology Biologics / Targeted Therapy
Description

DMR-002 is the second program in Damora's pipeline, targeting mutant CALR-driven myeloproliferative neoplasms through a distinct modality from DMR-001, progressing through discovery and IND-enabling stages toward clinical development to address the full spectrum of MPN patients.

3DMR-003
CategoryOncology Biologics / Targeted Therapy
Description

DMR-003 is the third program in Damora's pipeline, targeting mutant CALR-driven myeloproliferative neoplasms through an additional modality to provide portfolio optionality across the full spectrum of MPN patients.

4DMR-004
CategoryOncology Biologics / Targeted Therapy
Description

DMR-004 is the fourth program in Damora's pipeline, targeting mutant CALR-driven myeloproliferative neoplasms through an additional modality to provide portfolio optionality across the full spectrum of MPN patients.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-03-23
Description

CEO Jennifer Jarrett previously served as COO and CFO at Arcus Biosciences. While not an active partnership, this represents the executive's background and potential network connection to another oncology-focused biotechnology company.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-09
Description

Galecto, Inc. acquired Damora Therapeutics, Inc., with Damora subsequently rebranding from Galecto Inc. The acquisition brought mutant calreticulin-targeted therapies for rare blood cancers under the Damora name. Following the acquisition, Damora secured approximately $284.9 million through an oversubscribed private placement and $316 million public offering to fund operations and pipeline development.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Disc Medicine is a clinical-stage hematology company developing therapeutics for serious hematologic diseases, including programs targeting erythropoietic protoporphyria and other rare blood disorders. It represents an emerging player in the rare blood disease space with comparable clinical-stage positioning.

TypeEmerging player
Description

Geron markets imetelstat (Rytelo) for transfusion-dependent anemia in lower-risk MDS, with development programs extending into myelofibrosis. As a hematology-focused emerging player with a recently approved oncology product, Geron is a comparable clinical-to-commercial stage MPN competitor.

TypeOthers
Description

Ionis is an established RNA-targeted therapeutics platform company with development programs in hematology/oncology. While not directly competing in MPNs, Ionis represents a comparable biologics-platform biotech with expertise in targeted therapeutics development for rare diseases.

4Bristol-Myers Squibb
TypeBroad incumbent
Description

BMS markets fedratinib (Inrebic) for myelofibrosis, directly competing in the MPN market. As a large pharmaceutical incumbent with established hematology/oncology commercial infrastructure, BMS is a significant competitor for Damora's DMR-001 in the same indication.

TypeDirect peer
Description

GSK acquired Sierra Oncology and markets momelotinib (Omjjara) for myelofibrosis, a direct competitor to DMR-001 in the same patient population. The presence of multiple JAK inhibitors in MF demonstrates the competitive landscape Damora will face at launch.

TypeDirect peer
Description

Sobi acquired CTI BioPharma and markets pacritinib (Vonjo) for myelofibrosis patients with severe thrombocytopenia, a direct competitor in the MF space. Sobi represents a direct peer with a marketed MPN product and established rare disease commercial infrastructure.

TypeEmerging player
Description

Syndax is a clinical-stage oncology company developing axatilimab for chronic graft-versus-host disease and other hematology indications. CEO Jennifer Jarrett serves on Syndax's board, and the company represents a comparable clinical-stage hematology/oncology peer in size and stage.

TypeDirect peer
Description

Incyte's ruxolitinib (Jakafi) is the leading approved therapy for myelofibrosis, making Incyte the dominant direct competitor in the MPN space. Damora's DMR-001 will be evaluated against this established standard of care in the same patient population.

TypeOthers
Description

Blueprint Medicines is the prior employer of much of Damora's leadership team (CEO Jarrett, COO Sattarzadeh, CMO Hewes, CCAO Baker) and developed AYVAKIT for systemic mastocytosis. While not directly competing in MPNs, Blueprint is a strategic comparator in rare hematology/oncology drug development.

TypeEmerging player
Description

MorphoSys (acquired by Novartis) acquired Constellation Pharmaceuticals and developed pelabresib (CPI-0610) for myelofibrosis as a BET inhibitor. As a developer of novel MPN therapies, it represents a comparable clinical-stage player in the same disease space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Damora Therapeutics

Oncology Biopharmaceuticalsdamoratx.com

Damora Therapeutics is a pre-revenue, clinical-stage biotechnology company developing monoclonal antibody biologics targeting mutant calreticulin for the treatment of mutant CALR-driven myeloproliferative neoplasms (essential thrombocythemia and myelofibrosis), serving an addressable U.S. population of approximately 42,000 patients.

What Damora Therapeutics does

Damora Therapeutics (NASDAQ: DMRA) is a pre-revenue, clinical-stage biotechnology company headquartered in the Boston area and domiciled in Massachusetts, developing a new generation of disease-modifying monoclonal antibody biologics targeting mutant calreticulin (mutCALR), the disease driver in approximately 25% of essential thrombocythemia and 35% of myelofibrosis cases, a U.S. patient population of roughly 42,000. The lead asset, DMR-001, is engineered for exclusive mutCALR binding, with preclinical data showing approximately 10-fold potency gain against Type 2 mutant cells and approximately 5-fold half-life extension versus a relevant reference antibody, enabling subcutaneous autoinjector administration. The pipeline contains four programs (DMR-001 through DMR-004) using diverse modalities across the Type 1 and Type 2 CALR mutation spectrum, with regulatory submission for DMR-001 planned for mid-2026 and proof-of-concept clinical datasets expected beginning mid-2027.

The company was formed via Galecto, Inc.'s November 2025 acquisition of the original Damora Therapeutics and a concurrent oversubscribed private placement of approximately $284.9 million, followed by rebranding from Galecto to Damora and a $316 million public offering in March 2026. The cash position was approximately $532.9 million as of March 31, 2026, funding operations into 2029. Leadership is anchored by CEO Jennifer Jarrett (former COO/CFO of Arcus Biosciences, CFO of Medivation) alongside several former Blueprint Medicines executives (COO Sherwin Sattarzadeh, CMO Dr. Becker Hewes, CCO Jim Baker) and a board chaired by Peter Harwin of Fairmount Funds Management.

The business model is contingent on regulatory approval. Planned go-to-market channels include pharmaceutical distribution through specialty pharmacies, hospital buying groups, and academic medical centers, leveraging the subcutaneous autoinjector format for patient self-administration. Pricing has not been publicly disclosed. Sell-side analysts at TD Cowen, RBC Capital, Evercore ISI, and Leerink project peak sales of approximately $3.3 billion for DMR-001 in myelofibrosis and $3 billion in essential thrombocythemia. FY2025 net loss was approximately $209.84 million and Q1 2026 net loss was $27.8 million, reflecting elevated R&D investment ahead of clinical trials.

Damora Therapeutics firmographics

Firmographics
Name
Damora Therapeutics
Legal name
Damora Therapeutics, Inc.
Website
https://damoratx.com
Company type
Public
Founded year
2025
Operating status
Operating
Headcount range
11–50 employees
Short description
Damora Therapeutics is a pre-revenue, clinical-stage biotechnology company developing monoclonal antibody biologics targeting mutant calreticulin for the treatment of mutant CALR-driven myeloproliferative neoplasms (essential thrombocythemia and myelofibrosis), serving an addressable U.S. population of approximately 42,000 patients.
Ownership category
akta.pro rank

Damora Therapeutics industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAL
Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Monoclonal antibody therapy
  • Myeloproliferative neoplasm treatment
  • Rare disease biologics
  • Oncology drug development
  • Calreticulin targeted therapeutics

Where Damora Therapeutics is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Damora Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

  1. Pharmaceutical Product Sales: Damora Therapeutics is a pre-revenue biotechnology company that has not yet commercialized any products. The company is developing DMR-001 and additional pipeline assets for mutant CALR-driven myeloproliferative neoplasms. Upon regulatory approval, the company plans to generate revenue through the sale of pharmaceutical products, initially focusing on the U.S. market with plans for global expansion through clinical development.
  2. Potential Licensing and Partnership Revenue: As a development-stage biotech company, Damora may pursue licensing agreements, co-development partnerships, or strategic collaborations to advance its pipeline and generate revenue. TD Cowen coverage cited $3.3 billion peak sales forecast for DMR-001 in myelofibrosis and $3 billion in essential thrombocythemia, indicating significant commercial potential.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Damora Therapeutics product offering

Product offering

Core offering

Damora Therapeutics develops a pipeline of investigational monoclonal antibody therapeutics designed to exclusively target mutant calreticulin (mutCALR) for the treatment of myeloproliferative neoplasms, specifically Essential Thrombocythemia and Myelofibrosis. The lead asset, DMR-001, is engineered with clinically validated half-life extension technology to enable convenient, infrequent subcutaneous administration via autoinjector, offering a first-in-class disease-modifying approach for approximately 42,000 U.S. patients with no currently approved targeted therapy available.

Product overview

Damora Therapeutics is developing a pipeline of targeted biologics (monoclonal antibodies) for mutant calreticulin-driven myeloproliferative neoplasms (MPNs). The company's lead asset is DMR-001, an investigational monoclonal antibody therapy targeting mutCALR with best-in-class potential. The pipeline includes multiple programs (DMR-001, DMR-002, DMR-003, DMR-004) all targeting the same disease driver but leveraging diverse modalities to address the full spectrum of MPN patients. DMR-001 is the most advanced, with plans for regulatory submission in mid-2026 and Phase 1/1b clinical trial initiation, with proof-of-concept data expected beginning mid-2027.

Differentiator

Problem solved

Functional benefit

Products and services

  • DMR-001 DMR-001 is an investigational monoclonal antibody therapy targeting mutant calreticulin (mutCALR) with best-in-class potential for treating Essential Thrombocythemia (ET) and Myelofibrosis (MF). It is engineered for high selectivity and potency, with extended half-life to enable convenient, infrequent subcutaneous administration via autoinjector. Preclinical data show approximately 10-fold higher potency against Type 2 mutant cells and approximately 5-fold longer half-life compared to a reference antibody. Damora plans regulatory submission in mid-2026 to enable a global Phase 1/1b trial, with proof-of-concept data expected beginning in mid-2027.
  • DMR-002 DMR-002 is the second program in Damora's pipeline, targeting mutant CALR-driven myeloproliferative neoplasms through a distinct modality from DMR-001, progressing through discovery and IND-enabling stages toward clinical development to address the full spectrum of MPN patients.
  • DMR-003 DMR-003 is the third program in Damora's pipeline, targeting mutant CALR-driven myeloproliferative neoplasms through an additional modality to provide portfolio optionality across the full spectrum of MPN patients.
  • DMR-004 DMR-004 is the fourth program in Damora's pipeline, targeting mutant CALR-driven myeloproliferative neoplasms through an additional modality to provide portfolio optionality across the full spectrum of MPN patients.

Quantifiable outcome

  • 10-fold increase in potency against Type 2 mutant cells compared to reference antibody
  • +3 more outcomes

Companies that use Damora Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Damora Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Damora Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • Arcus BiosciencesminorStrategic or Co-development Partner · 23 March 2026CEO Jennifer Jarrett previously served as COO and CFO at Arcus Biosciences. While not an active partnership, this represents the executive's background and potential network connection to another oncology-focused biotechnology company.
  • Galecto, Inc.coreStrategic or Co-development Partner · 9 November 2025Galecto, Inc. acquired Damora Therapeutics, Inc., with Damora subsequently rebranding from Galecto Inc. The acquisition brought mutant calreticulin-targeted therapies for rare blood cancers under the Damora name. Following the acquisition, Damora secured approximately $284.9 million through an oversubscribed private placement and $316 million public offering to fund operations and pipeline development.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Damora Therapeutics competitors and assessment

Company assessment

Emerging players

  • Disc Medicine: Disc Medicine is a clinical-stage hematology company developing therapeutics for serious hematologic diseases, including programs targeting erythropoietic protoporphyria and other rare blood disorders. It represents an emerging player in the rare blood disease space with comparable clinical-stage positioning.
  • Geron Corporation: Geron markets imetelstat (Rytelo) for transfusion-dependent anemia in lower-risk MDS, with development programs extending into myelofibrosis. As a hematology-focused emerging player with a recently approved oncology product, Geron is a comparable clinical-to-commercial stage MPN competitor.
  • Syndax Pharmaceuticals: Syndax is a clinical-stage oncology company developing axatilimab for chronic graft-versus-host disease and other hematology indications. CEO Jennifer Jarrett serves on Syndax's board, and the company represents a comparable clinical-stage hematology/oncology peer in size and stage.
  • MorphoSys (now part of Novartis): MorphoSys (acquired by Novartis) acquired Constellation Pharmaceuticals and developed pelabresib (CPI-0610) for myelofibrosis as a BET inhibitor. As a developer of novel MPN therapies, it represents a comparable clinical-stage player in the same disease space.

Others

  • Ionis Pharmaceuticals: Ionis is an established RNA-targeted therapeutics platform company with development programs in hematology/oncology. While not directly competing in MPNs, Ionis represents a comparable biologics-platform biotech with expertise in targeted therapeutics development for rare diseases.
  • Blueprint Medicines: Blueprint Medicines is the prior employer of much of Damora's leadership team (CEO Jarrett, COO Sattarzadeh, CMO Hewes, CCAO Baker) and developed AYVAKIT for systemic mastocytosis. While not directly competing in MPNs, Blueprint is a strategic comparator in rare hematology/oncology drug development.

Broad incumbents

  • Bristol-Myers Squibb: BMS markets fedratinib (Inrebic) for myelofibrosis, directly competing in the MPN market. As a large pharmaceutical incumbent with established hematology/oncology commercial infrastructure, BMS is a significant competitor for Damora's DMR-001 in the same indication.

Direct peers

  • GSK (Sierra Oncology): GSK acquired Sierra Oncology and markets momelotinib (Omjjara) for myelofibrosis, a direct competitor to DMR-001 in the same patient population. The presence of multiple JAK inhibitors in MF demonstrates the competitive landscape Damora will face at launch.
  • Sobi (Swedish Orphan Biovitrum): Sobi acquired CTI BioPharma and markets pacritinib (Vonjo) for myelofibrosis patients with severe thrombocytopenia, a direct competitor in the MF space. Sobi represents a direct peer with a marketed MPN product and established rare disease commercial infrastructure.
  • Incyte: Incyte's ruxolitinib (Jakafi) is the leading approved therapy for myelofibrosis, making Incyte the dominant direct competitor in the MPN space. Damora's DMR-001 will be evaluated against this established standard of care in the same patient population.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Damora Therapeutics social profiles

Digital presence

Damora Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Damora Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

Damora Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Damora Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Damora Therapeutics

What does Damora Therapeutics do?

Damora Therapeutics develops a pipeline of investigational monoclonal antibody therapeutics designed to exclusively target mutant calreticulin (mutCALR) for the treatment of myeloproliferative neoplasms, specifically Essential Thrombocythemia and Myelofibrosis. The lead asset, DMR-001, is engineered with clinically validated half-life extension technology to enable convenient, infrequent subcutaneous administration via autoinjector, offering a first-in-class disease-modifying approach for approximately 42,000 U.S. patients with no currently approved targeted therapy available.

Is Damora Therapeutics a public or private company?

Damora Therapeutics is a public company. It is classified as public and is currently operating.

When was Damora Therapeutics founded?

Damora Therapeutics was founded in 2025. It employs 11 to 50 people.

Where is Damora Therapeutics based?

Damora Therapeutics is headquartered in Waltham, United States, in the North America region.

How does Damora Therapeutics make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are potential Licensing and Partnership Revenue.

Who are Damora Therapeutics's main competitors?

Emerging players on record are Disc Medicine, Geron Corporation, Syndax Pharmaceuticals and MorphoSys (now part of Novartis). Others are Ionis Pharmaceuticals and Blueprint Medicines. Bristol-Myers Squibb is listed as a broad incumbent. Direct peers are GSK (Sierra Oncology), Sobi (Swedish Orphan Biovitrum) and Incyte.

Does Damora Therapeutics have an API?

No public API is recorded for Damora Therapeutics.

What industry is Damora Therapeutics in?

Damora Therapeutics's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAL, Blood Factors & Hemostasis Biologics (recombinant clotting factors, thrombolytics). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comDamora at Jefferies Global Healthcare Conference: CALR pushDamora outlined its mutant CALR antibody DMR-001 at the Jefferies Global Healthcare Conference, targeting essential thrombocythemia and myelofibrosis. The company estimates a U.S. market of about 45,000 patients and over $10 billion, with a Phase I/IB study open in Australia and the U.S. It positions its subcutaneous dosing and type 2 activity as advantages over Incyte's program.Seeking AlphaDamora Therapeutics, Inc. (DMRA) Presents at UBS Global Biopharma Conference 2026 TranscriptDamora Therapeutics, a Fairmount company, presented at the UBS Global Biopharma Conference 2026, with CEO Jennifer Jarrett and COO Sherwin Sattarzadeh introducing the company. The company focuses on hematological diseases, specifically essential thrombocythemia and myelofibrosis, and is the sixth Fairmount-founded company.Investing.comDamora Therapeutics at Guggenheim conference: cash, pipeline driveDamora Therapeutics outlined its mutCALR antibody franchise at the Guggenheim conference, citing $530 million in cash and a $5 billion U.S. MPN opportunity. Its lead asset DMR-001 targets pan-mutant CALR with subcutaneous dosing, and Phase I CLARITY-101 is enrolling up to 250 patients. The company expects proof-of-concept data in mid-2027 and Phase III in mid-2028.American Banking and Market NewsDamora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Has Consensus Price Target of $46.38 According to BrokeragesDamora Therapeutics stock has a consensus "Buy" rating with a $46.38 price target from 12 analysts. CEO Jennifer Jarrett bought 12,500 shares at $20.23, increasing her stake by 2.5%. The company reported Q2 EPS of -$0.40, beating the -$0.52 consensus.American Banking and Market NewsGuggenheim Initiates Coverage on Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)Guggenheim initiated coverage on Damora Therapeutics with a Buy rating and a $59 price target, implying 148.95% upside from the previous close. The stock opened at $23.70, and the consensus rating is Buy with an average target of $46.38. CEO Jennifer Jarrett bought 12,500 shares at $20.23 each.American Banking and Market NewsDamora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Bumped Up to “Hold” by Wall Street ZenWall Street Zen upgraded Damora Therapeutics from sell to hold, while other analysts have mixed ratings. The stock has a consensus Buy rating with an average target of $46.38, and the company reported Q3 EPS of -$0.40, beating estimates. CEO Jennifer Jarrett bought 12,500 shares at $20.23.TradingViewGuggenheim maintains Damora Therapeutics at Buy, lowers price target to $59 from $60Guggenheim maintained Damora Therapeutics at Buy and lowered its price target to $59 from $60. The target implies an upside of 169.9% from the Nov 5 close of $21.86.MarketBeatDamora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Cut to Sell at Wall Street ZenWall Street Zen downgraded Damora Therapeutics from hold to sell, while other analysts have mixed ratings. The stock opened at $21.49, with a consensus price target of $46.50. CEO Jennifer Jarrett bought 12,500 shares at $20.23 each.American Banking and Market NewsDamora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Rating Lowered by Wall Street ZenWall Street Zen downgraded Damora Therapeutics from hold to sell, while TD Cowen upgraded to strong-buy and HC Wainwright reaffirmed buy. The stock has a consensus Buy rating with a $46.50 target, and CEO Jennifer Jarrett bought 12,500 shares at $20.23.MarketBeatDamora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Price Up 6.9% - Here's What HappenedDamora Therapeutics stock rose 6.9% to $19.72 on Monday, with volume down 81% from average. Analysts rate the stock Buy with a $46.50 average target, and CEO Jennifer Jarrett bought 12,500 shares at $20.23. The company's lead candidate GB2064 is in Phase IIa for myelofibrosis.